LUMOXITI

NDC auxiliary status#

Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded package	package	0310-4700	0310-4700-01	D	Discontinued by firm		2026-07-31

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
0310-4700-01	EA - Each	0310-4700	6eeef17f-51cc-4839-9988-3b65777dffad	1	2018-11-06

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761104	Lumoxiti	moxetumomab pasudotox-tdfk	351(a)	Disc	2026-06-01

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
2NDX4B6N8F	MOXETUMOMAB PASUDOTOX	1020748-57-5	MOXETUMOMAB PASUDOTOX

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Units	Marketing start	Marketing end	Sample	Exclude flag	Status
0310-4700-01	00310470001	1 VIAL in 1 CARTON (0310-4700-01) > 1 mL in 1 VIAL	1 vial	2018-10-24	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
LUMOXITI	AstraZeneca Pharmaceuticals LP \| AstraZeneca PLC	2022-02-08	HUMAN PRESCRIPTION DRUG LABEL	13